Fewer Proprietary Drug Names Rejected With FDA, Industry On Same Page
This article was originally published in The Tan Sheet
Executive Summary
After several false starts, FDA and the pharma industry appear to be on the same page about vetting potential brand names for new drugs. FDA’s rate of rejecting proposed brand names has dropped from 50% or higher when the decade began to about 25%, according to Office of Surveillance and Epidemiology data.
You may also be interested in...
OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
The trade group recommends FDA write a separate proprietary name guidance for OTC drugs. FDA’s draft guidance also renders useless OTC manufacturers’ expertise in conducting tests to determine whether consumers safely self-select nonprescription drugs based on labeling, CHPA says in comments.
New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Mandatory Efficacy Trials: US FDA Affirms Broad Scope Of New Post-Market Authority
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: